The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on the reclassification of two progestogen-only contraceptive pills containing desogestrel.
The consultation affects two products containing desogestrel; Lovima 75 microgram film-coated tablets and Hana 75 microgram film-coated tablets. Lovima and Hana are both oral contraceptives for continuous use to prevent pregnancy in those of childbearing age.
This is the first time such a change has been considered and the MHRA is asking the public and stakeholders for their views on whether these two products should become a pharmacy medicine and available over the counter, without a medical prescription.
If the outcome leads to the two products being reclassified, pharmacists will have access to training materials and a checklist to enable them to identify women who can be supplied this medicine safely. Contraceptive pills containing desogestrel will still be available on prescription from GPs and sexual health clinics.
The Commission on Human Medicines has advised that it is safe for these is products to be made available as a Pharmacy (P) medicines and consultations are open until 5 March.
Dr Sarah Branch, Director of Vigilance and Risk Management of Medicines at the MHRA, said: “Every response received will help us gain a better picture of whether people think the contraceptive pill with desogestrel should be available over the counter. We hope to hear from as many people and women’s groups as possible.”